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Abstract
This review presents a comprehensive overview on selected synthetic routes towards commercial drug compounds as published in
both journal and patent literature. Owing to the vast number of potential structures, we have concentrated only on those drugs
containing five-membered heterocycles and focused principally on the assembly of the heterocyclic core. In order to target the most
representative chemical entities the examples discussed have been selected from the top 200 best selling drugs of recent years.
Introduction
Over the past few decades organic chemistry has seen
tremendous progress and this has enabled the synthetic chemist
to assemble virtually any molecular structure imaginable given
reasonable time and sufficient resources. A steady increase in
architectural complexity and the incorporation of more diverse
molecular functionality has been a notable feature of pharma-
ceutical research and development. This general trend has
emerged as a consequence of the better understanding of the
genome and has resulted in many highly specific therapeutic
targets being elucidated.
However, even today it might be argued that because of the
perceived simpler structures of drug molecules when compared
to complex natural products, only a limited repertoire of syn-
thetic transformations are utilised for their construction.
Furthermore, many of the modern pioneering developments in
organic synthesis including new highly selective and mild bond
forming reactions such as metathesis and C–H activation, asym-
metric transformations as well as polymer- and technology-
assisted syntheses are underused.
In order to evaluate the validity of this hypothesis we decided to
investigate the syntheses of the best-selling pharmaceutical
substances focusing not only on the type of transformations
involved but more importantly on the way the heterocyclic
components were assembled. Aromatic and non-aromatic
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Table 1: Heterocylic structures discussed in this review.
Name Label Structure Heterocycle core
atorvastatin 1 pyrrole Figure 1
sunitinib 36 pyrrole Scheme 7
sumatriptan 49 indole Scheme 9
zolmitriptan 50 indole Scheme 9
naratriptan 69 indole Scheme 15
rizatriptan 76 indole Scheme 17
heterocyclic rings are a predominant architectural constant of
pharmaceuticals and allow for variable interactions with the
biological target which are not possible using simpler
carbocyclic motifs. Based on our observations, we will
moreover be able to evaluate the degree these privileged
structures utilise innovative and challenging synthetic
strategies. In addition, it will be possible to establish which
reactions are most frequently employed and which ones are
surprisingly rare or notably absent. Furthermore, from this
study it will be possible to judge whether novel methods
and transformations developed within the academic
community are commonly applied in the later stages of drug
research.
In order to illustrate the diversity of synthetic methods used by
the pharmaceutical industry to generate heterocycle containing
molecules we decided in the first part of this review to focus
mainly on five-membered aromatic heterocycles represented
within the top 200 best selling drugs [1,2]. This review abstracts
information available from many literature sources including
patents to provide a selection of the most commonly used routes
in drug synthesis. Different heterocyclic structures will be intro-
duced and discussed in individual subsections. In Table 1 a
summary of these structures is shown. We believe that this
article will give an enlightening overview of both the classical
heterocycle syntheses as well as interesting but less used trans-
formations.
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Table 1: Heterocylic structures discussed in this review. (continued)
eletriptan 87 indole Scheme 20
fluvastatin 2 indole Scheme 25
ondansetron 119 indole Scheme 27
tadalafil 132 indole Scheme 28
carvedilol 136 carbazole Figure 4
etodolac 153 carbazole(analogue) Scheme 31
losartan 157 imidazole Figure 5
olmesartan 158 imidazole Scheme 36
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Table 1: Heterocylic structures discussed in this review. (continued)
ondansetron 119 imidazole Scheme 37
esomeprazole 190 benzimidazole Scheme 39
pantoprazole 193 benzimidazole Scheme 40
candesartan 204 benzimidazole Scheme 41
telmisartan 217 benzimidazole Scheme 43
zolpidem 227 imidazopyridine Scheme 45
celecoxib 235 pyrazole Figure 7
pazopanib 246 indazole Scheme 50
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Table 1: Heterocylic structures discussed in this review. (continued)
anastrozole 257 1,2,4-triazole Scheme 51
rizatriptan 76 1,2,4-triazole Scheme 51
letrozole 256 1,2,4-triazole Scheme 51
sitagliptin 275 1,2,4-triazole Scheme 55
maraviroc 286 1,2,4-triazole Scheme 57
alprazolam 297 1,2,4-triazole Scheme 58
itraconazole 307 1,2,4-triazole Figure 9
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Table 1: Heterocylic structures discussed in this review. (continued)
rufinamide 315 1,2,3-triazole Scheme 61
valsartan 319 tetrazole Scheme 62
losartan 157 tetrazole Scheme 63
cilostazole 325 tetrazole Scheme 64
cefdinir 329 thiazole Figure 11
ritonavir 337 thiazole Scheme 66
pramipexole 345 thiazole Scheme 67
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Table 1: Heterocylic structures discussed in this review. (continued)
famotidine 352 thiazole Scheme 69
febuxostat 359 thiazole Scheme 70
ziprasidone 367 thiazole Scheme 71
ranitidine 377 furan Scheme 73
nitrofurantoin 382 furan Scheme 74
amiodaron 385 furan Scheme 76
raloxifene 392 thiophene Scheme 77
olanzapine 399 thiophene Scheme 79
clopidogrel 420 thiophene Scheme 81
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Table 1: Heterocylic structures discussed in this review. (continued)
timolol 432 thiadiazole Figure 14
tizanidine 440 thiadiazole Scheme 85
leflunomide 446 isoxazole Scheme 86
sulfamethoxazole 447 isoxazole Scheme 87
risperidone 454 benzoisoxazole Scheme 88
Review
Pyrroles
Pyrrole, a five-membered nitrogen containing heterocycle is
present in some of the most common biologically important
molecules, i.e., chlorophyll and haem. However, while the
pyrrole ring is not widely represented in pharmaceutical com-
pounds, the core structure of atorvastatin (1, Lipitor; Figure 1),
the best-selling drug substance of the last few years, does
contain a penta-substituted pyrrole ring. This drug is an
example of a competitive HMG-CoA-reductase inhibitor
belonging to the 7-substituted 3,5-dihydroxyheptanoic
acid family. In atorvastatin this important syn-1,3-diol
moiety is connected to the other functional constituents
through a fully substituted pyrrole ring instead of the more
elaborate systems which are encountered in other members of
this family.
The initial synthesis of atorvastatin was reported by the
Warner–Lambert company [3]. From structure–activity relation-
ship (SAR) studies it was found that the addition of substitu-
ents at the 3- and 4-position of the pyrrole scaffold signifi-
cantly increases potency when compared to the more classical
2,5-disubstituted pyrroles. This study culminated in the
discovery of atorvastatin which has a five times greater potency
Figure 1: Structures of atorvastatin and other commercial statins.
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Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 1: Synthesis of pentasubstituted pyrroles.
then the initial lead, the fungal metabolite compactin (5,
Figure 2).
Figure 2: Structure of compactin.
Although it was possible to construct such fully substituted
pyrrole rings by ZnCl2-catalysed condensation reactions
between a functionalised enamine 6 and simple benzoin (7), this
method proved to be less successful for more complex pyrroles
of which atorvastatin was an example (Scheme 1).
In order to prepare the 5-isopropylpyrrole derivative 16 a more
efficient [3 + 2] cycloaddition of an acetylene component with
an amido acid 13 was developed. Unfortunately, reacting ethyl
phenylpropiolate with the corresponding amido acid in hot
acetic anhydride afforded a 4:1 mixture of regioisomers with
the major product being the undesired regioisomer (Scheme 2).
However, the analogous reaction with isomer 19 was found to
be completely regiospecific leading to the formation of the
desired product 16 albeit in only moderate yield (Scheme 3).
By modification of the coupling partners a more defined dipolar
[3 + 2] cycloaddition between N,3-diphenylpropynamide (22)
and an in situ generated mesoionic species 21 furnished the
desired product 23 regiospecifically [4] (Scheme 4).
A further synthetic approach was based on the classical
Paal–Knorr cyclocondensation of a highly substituted 1,4-
diketone with a primary amine bearing a masked aldehyde func-
tionality. The 1,4-diketone component, which can be accessed
via a 3-step sequence [5] starting from aniline, was refluxed
with 3-aminopropionaldehyde diethylacetal 32 in toluene under
mildly acidic conditions to afford the fully substituted pyrrole
motif in 81% isolated yield following crystallisation [6]. The
key transformation in this sequence is a thiazolium-mediated
Stetter reaction between 4-fluorobenzaldehyde (29) and an
advanced Michael acceptor obtained from an initial Knoeven-
agel condensation (Scheme 5).
In order to improve the overall yield as well as the convergency,
the industrial route [7] introduced the fully elaborated side
chain 34 by condensation with the previously described 1,4-
diketone 31 (Scheme 5 and Scheme 6). The desired atorvastatin
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 7: Synthesis of sunitinib.
structure was then obtained in only three additional steps via
acetal cleavage, ester hydrolysis and formation of the calcium
salt.
Scheme 6: Convergent synthesis towards atorvastatin.
Sunitinib (36, Sutent) is Pfizer’s novel receptor tyrosine kinase
inhibitor (RTK) approved in 2006 by the FDA for the treatment
of both renal cell carcinoma and gastrointestinal stromal
tumors. This drug has been suggested as a second-line therapy
for patients developing mutation-related resistance to other
cancer medications such as imatinib (Gleevec). Sunitinib binds
to the inactivated, auto-inhibited conformation of the KIT
kinase by partially occupying the space normally filled by the
ADP’s adenine in the phosphorylated protein. The indolinone
section is located in a deeper pocket with the heteroatoms being
involved in H-bonding glutamate and tyrosine residues whilst
the pyrrole ring and the diethylaminoethyl appendage are
exposed to the solvent environment [8] (Figure 3).
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Structurally, this medication consists of a complex pyrrole-
substituted 2-indolinone core which can be prepared by a late
stage aldol condensation between a 2-indolinone fragment 42
with the corresponding pyrrole aldehyde 41 (Scheme 7). The
oxime functionality in compound 38, which is obtained by
nitrosation of tert-butyl acetoacetate (37) [9], is reduced by zinc
to give an unstable aminoketone intermediate. Subsequent
enamine formation and ring closure affords the fully substi-
tuted pyrrole ring 40. Selective deprotection of the tert-butyl
ester with concomitant decarboxylation yields ethyl 2,4-
dimethylpyrrole-3-carboxylate which can be formylated at the
free ring position by trimethyl orthoformate to yield the fully
elaborated pyrrole aldehyde (41). The aforementioned aldol
condensation unites both key fragments: Ester hydrolysis and
amide formation complete the synthesis (Scheme 7).
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
An attractive alternative synthesis of sunitinib introduces the
amide side chain earlier by ring opening of 4-methyleneoxetan-
2-one (43) with N,N-diethylethane-1,2-diamine (44) [10]. The
resulting β-keto amide 45 is then converted to the analogous
pyrrole by condensation with the previously mentioned oxime
38 under reductive conditions. Deprotection and decarboxyl-
ation of the remaining tert-butyl ester produces the desired
pyrrole intermediate, which upon treatment with Vilsmeier
reagent undergoes a formal acylation. This product is not iso-
lated but reacted directly with 41 in an aldol condensation to
yield sunitinib (Scheme 8).
Indoles
The neuroamine transmitter serotonin contains an indole ring,
so it is not surprising that indoles are a recurring theme in many
drugs affecting central nervous system (CNS) function
including antidepressants, antipsychotics, anxiolytics and anti-
migraine drugs, as well as psychedelic agents. Indole is also one
of the best represented heterocyclic motifs present in the top
selling pharmaceuticals, being found in eight of the top 200
drugs, with five of these belonging to the triptan family of anti-
migraine treatments. The classical Fischer indole synthesis is
usually reported as one of the first choice routes to prepare
these scaffolds. Drugs such as GSK’s serotonin receptor modu-
lators sumatriptan (49, Imitrex) and zolmitriptan (50, Zomig)
use the Fischer indole synthesis at a late stage in order to form
the desired compound albeit in only low to moderate yields
(Scheme 9).
However, in sumatriptan the indole product resulting from the
Fischer synthesis can still react further which leads to the for-
mation of by-products and significantly reduced yields. One
way to minimise this was to protect the nitrogen of the sulfon-
amide group prior to indole formation [11]. This leads not only
to an increased yield in the indole forming step (to 50%) but
also facilitates chromatographic purification. The dimethyl-
amino group can be present from the beginning of the synthesis
or can be introduced via displacement of chloride or reduction
of a cyano moiety. Alternatively, the dimethyl ethylene amine
side chain can be introduced in position 3 via a Friedel–Crafts-
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
type acylation. The resulting acid chloride is transformed in situ
to the corresponding amide which on reduction with lithium
aluminium hydride affords sumatriptan (Scheme 10) [12].
In the standard Fischer indole synthesis a hydrazine, which is
most commonly derived from the corresponding diazonium salt,
is reacted with a suitable carbonyl compound. Alternatively, the
Japp–Klingemann reaction can be used to directly couple the
diazonium salt with a β-ketoester to obtain a hydrazone which
can then undergo indole ring formation (Scheme 11) [13].
As can be seen from Scheme 11 the indole 59 prepared via the
Japp–Klingemann reaction is substituted at position 2 by an
ester group which prevents reaction with electrophiles, thereby
reducing the amount of undesired by-products. A simple
sequence of hydrolysis and decarboxylation then affords suma-
triptan [14].
All the reported methods for the synthesis of sumatriptan begin
with the sulfonamide group already present on the aromatic ring
and several routes are possible to introduce this functional
group. The scalable route to the sulfonamides inevitably
involves the preparation of the sulfonyl chloride intermediate
which is then trapped with the desired amine. The sulfonyl
chloride can also be prepared from the corresponding hemithio-
acetal 61  by treatment with NCS in wet acetic acid
(Scheme 12). This efficient oxidation produces only methanol
and formaldehyde as by-products [15].
Another possible approach is based on the direct displacement
of a benzylic chloride by sodium sulfite and subsequent sulfon-
amide formation as shown in Scheme 13 [16].
A more recent method utilises a palladium-catalysed Negishi
coupling to access a diverse library of benzylic sulfonamides,
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and
63.
Scheme 13: Alternative introduction of the sulfonamide.
all prepared in high yields. As this route employs sulfonamide-
stabilised anions the preparation and handling of unstable
sulfonyl chloride intermediates is therefore circumvented
(Scheme 14) [17].
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
An analogous Heck reaction approach has also been employed
to introduce a homologous side chain as demonstrated during
the assembly of the antimigraine drug naratriptan (69, Amerge,
Scheme 15) [18].
Another related antimigraine drug developed by GSK is
zolmitriptan (Zomig, 50). The indole ring and its substitution at
the 3-position are identical to that of sumatriptan, however, the
sulfonamide side chain has been replaced by an oxazolinone
ring. The original synthesis utilised 4-nitro-L-phenylalanine
(73) as the precursor for the oxazoline moiety (Scheme 16)
[19]. The resulting Fischer indole synthesis is similar to that
used for sumatriptan (Scheme 9).
More recent reports [20] deal with improvements to both these
syntheses making them more economic and environmentally
benign. For example, the three steps to zolmitriptan, namely,
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
diazonium salt formation, its subsequent reduction and Fischer
indole synthesis can all be carried out in aqueous media without
the need for intermediate isolation. It has also been demon-
strated that the reduction of the initially formed diazonium salt
can be accomplished by using sodium metabisulfite (Na2S2O5)
rather than using the more toxic stannous chloride or the less
water soluble and more expensive sodium sulfite.
Preparation of the indole ring system in the antimigraine drug
rizatriptan (76, Maxalt) makes use of the Grandberg variation of
the Fischer indole synthesis as the final stage reaction to form
the tryptamine-type moiety, via formation and re-opening of a
tricyclic intermediate [21,22]. Although not a high yield
process, this one pot sequence establishes the indole ring and
the pendant primary amine group in a single operation
(Scheme 17).
However, the main disadvantage of this process is the need for
high temperatures which leads to the formation of dimeric
impurities and results in the requirement for extensive
chromatographic purification. An improved process which
circumvents the formation of such dimeric impurities involves
the reduction of the intermediate diazonium salt with sodium
sulfite and hydrochloric acid to form an easily isolable and crys-
talline phenylhydrazine sulfonic acid 81. The subsequent
Fischer indole synthesis can then be performed cleanly at much
lower temperatures (Scheme 18) and yields pure rizatriptan as
its benzoate salt [23]. In addition, the use of precursor 82,
already possesing the desired dimethylamino group, simplifies
the reaction sequence and tunes the reactivity of the amine
preventing it from participating in many side reactions.
The indole core of rizatriptan can also be prepared by a pal-
ladium-catalysed coupling first reported by Larock [24]. The
iodoaniline derivative 84 required for this approach can be
readily synthesised from triazolomethyl aniline 83 by treatment
with iodine monochloride in aqueous methanol. The bis-TES-
protected butynol 85 was found to be the most efficient coup-
ling partner and led smoothly to the desired indole 86.
Subsequent removal of the TES-groups and introduction of a di-
methylamino moiety furnishes the desired drug compound [25-
27] (Scheme 19).
Beilstein J. Org. Chem. 2011, 7, 442–495.
457
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Eletriptan (87, Relpax) is yet another indole-containing anti-
migraine drug. A process route for the synthesis of eletriptan
published by Pfizer starts from a preformed bromo-indole 88
[28] (Scheme 20). In order to perform the acylation of the
indole ring on larger scale, ethylmagnesium bromide and the
corresponding acid chloride 89 are added concurrently from two
different sides of the reactor to stop these reagents reacting with
each other. This method of adding the reagents circumvents the
necessity to isolate the magnesium salt of the indole and
increases the yield from 50 to 82%. The carbonyl group of the
proline side chain is then reduced simultaneously with the
complete reduction of the Cbz-group to a methyl group with
lithium aluminium hydride. Finally, the sulfonate side chain is
introduced via a Heck-type coupling similar to that of nara-
triptan (Scheme 15), followed by hydrogenation of the double
bond to afford eletriptan (Scheme 20).
A rather ingenious Mitsunobu coupling reaction has been used
to create a highly functionalised substrate 96 for an
intramolecular Heck reaction resulting in a very short and
succinct synthesis of eletriptan and related analogues 97 [29]
(Scheme 21).
Interestingly, it was found that the most obvious approach, the
direct Fischer indole synthesis, to prepare the core of eletriptan
as shown in Scheme 22 is not successful [30]. This is believed
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
to be due to the instability of the phenyl hydrazine species 98
under the relatively harsh reaction conditions required to
promote the cyclisation.
However, this problem could be avoided by using an acid-labile
oxalate protected hydrazine 104 as depicted in Scheme 23. The
yield of this step can be further improved up to 84% if the
corresponding calcium oxalate is used.
The Bischler–Möhlau reaction is an alternative indole synthesis
employing an α-bromo ketone and an excess of aniline to give a
2-arylindole derivative 110 [31] (Scheme 24). For a long time
this procedure has received little attention due to the require-
ment for rather extreme reaction conditions. However, the use
of microwave radiation in combination with Lewis acid cata-
lysis allows the reaction to be conducted much more efficiently
[32]. This gives mid range yields (50–70%) of the 2-arylindoles
over the two step sequence and tolerates a selection of func-
tional groups on the aniline ring.
Fluvastatin (2, Lescol), a HMG-CoA reductase inhibitor was
initially prepared by a Fischer indole synthesis [33]
(Scheme 25). However, in the development stages it was
decided that a Bischler–Möhlau type reaction could be used
instead. In this case a ZnCl2-mediated Bischler-type indole syn-
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
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Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
thesis [34] is used with stoichiometric amounts of the aniline
which leads to the required 3-substituted indole core 116 at an
early stage in the synthesis. A novel way to introduce a formyl
substituent at the 2-position of the indole was subsequently
developed to aid the introduction of the syn-diol pendant side-
chain.
A completely different strategy was used in the synthesis of the
serotonin 5-HT3 receptor antagonist ondansetron (119, Zofran).
In this synthesis a palladium-catalysed intramolecular Heck-
reaction was used to build the tricyclic indole core in a short
and concise sequence (Scheme 26) [35,36].
Alternatively, a direct Fischer indole synthesis between phenyl-
methyl hydrazine and a cyclic 1,3-dione derivative could be
utilised to prepare the desired fully substituted tricyclic core of
ondansetron (Scheme 27) [37].
A different approach was used in the synthesis of the phospho-
diesterase inhibitor tadalafil (132, Cialis) starting from commer-
cially available (D)-tryptophan methyl ester to form the
indolopiperidine motif 135 via a Pictet–Spengler reaction fol-
lowed by a double condensation to install the additional
diketopiperazine ring (Scheme 28) [38,39].
To achieve the high levels of cis selectivity required from the
Pictet–Spengler reaction, an extensive investigation of solvents
and the influence of additives was undertaken [40]. It was iden-
tified that the use of a specific 23 mol % of benzoic acid signifi-
cantly increased the cis/trans ratio from a base level of 55:45 to
92:8 (16 h reaction time at ambient temperature) in an overall
yield of 86%. It was also determined that more polar solvents
such as acetonitrile and nitromethane preferentially solvated the
trans product and thereby allowed the isolation of the cis com-
pound by precipitation. It was also shown that by heating the
reaction mixture under reflux the product distribution could be
driven to the thermodynamically more favoured cis isomer
having both the ester and the piperonyl moiety in equatorial
positions. Hence, after heating under reflux for 8 h the cis/trans
ratio was found to be 99:1 and the product could be isolated in
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
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Scheme 29: Synthesis of the carbazole core of carvedilol.
an overall yield of 91%. This work represents an impressive
example of a well considered and executed process optimisa-
tion study.
Carbazoles
Carvedilol (136, Coreg) is a general non-selective β-blocker,
used in the treatment of mild to moderate congestive heart
failure. The structure comprises of a core carbazole ring that
plays an important role in its increased activity.
The cardioprotective effect of β-adrenergic blockers is attri-
buted to their ability to reduce the myocardial workload by
reducing the system’s requirement for oxygen. However, the
activity of carvedilol is greater when compared to other
members of the β-blocker family such as propranolol (137,
Figure 4) implying that carvedilol has an additional antioxidant
mode of action. It has been proposed that the carbazole ring
may be involved in scavenging oxygen radicals thereby
accounting for reduced myocardial damage [41].
Figure 4: Structures of carvedilol 136 and propranolol 137.
Since carbazoles are similar to indoles, analogous methods can
be used for their synthesis. The key intermediate for carvedilol
is 4-hydroxy-9H-carbazole (141) [42]. In analogy to the Fischer
indole synthesis, cyclohexane-1,3-dione monophenyl hydrazone
139 is prepared via condensation of phenylhydrazine (138) with
1,3-cyclohexanedione (121, Scheme 29). This compound can
then undergo an acid catalysed Fischer indole synthesis to yield
tetrahydro-4-oxocarbazole 140. Various methods have been
described to dehydrogenate this intermediate including the use
of bromine, sulfur, LiCl/CuCl, lead dioxide, chloranil or pal-
ladium on charcoal. However, the need to use these reagents in
equal stoichiometry or even excess has led to the search for a
new approach. It was found that a catalytic quantity of Raney
nickel in an aqueous potassium hydroxide solution gives the
desired 4-hydroxy compound 141 cleanly and in high conver-
sion (Scheme 29).
Alternative routes to this key intermediate such as Ullmann-
type reactions have also been reported, however, these usually
rely on longer reaction sequences and require more expensive
starting materials (Scheme 30) [42,43].
Etodolac (153, Lodine) is a racemic non-steroidal anti-inflam-
matory tetrahydrocarbazole derivative used to treat inflamma-
tion and prescribed for general pain relief. Two general routes
have been described for the preparation of this drug. In the first
route the hydrazine 149 is prepared via the reduction of
diazonium salt 148 with tin(II) chloride and subjected to a
Fischer indole reaction with aldehyde 150. The resulting indole
is then condensed with ethyl 3-oxopropanoate followed by
saponification of the ester to yield etodolac (Scheme 31) [44].
The second described route [45,46] is similar but starts with a
more readily available carbonyl surrogate; 2,3-dihydrofuran
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
154. The Fischer indole reaction provides a primary alcohol
which is TMS-protected and condensed with methyl
3-oxopentanoate under Lewis acid conditions. The use of the
temporary silyl mask was found beneficial as it circumvents the
need for chromatographic purification. Finally, simple saponi-
fication furnishes etodolac (Scheme 32).
Beilstein J. Org. Chem. 2011, 7, 442–495.
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Figure 5: Structures of imidazole-containing drugs.
Extensive biological studies have found that the majority of the
reactivity of etodolac is derived from the (S)-(+)-enantiomer.
The resolution of the racemate can be readily accomplished
using cinchonine or the glucose derivative N-methyl-D-
glucamine. The latter provides the pure (S)-(+)-enantiomer in
25.3% yield (>96% de) after two crystallisations. In addition,
the racemisation of the undesired enantiomer via methyl ester
formation and treatment with sodium hydroxide was found to
be feasible allowing efficient recycling of this material [47].
Imidazoles
Imidazole is an important biological building block being
present in the amino acid histidine and possessing inherent cata-
lyst and acid–base functionality. An imidazole ring is also a
component of the biogenic amine histamine. It is interesting to
note that the imidazole ring does not however appear in the
most common H1 and H2 antagonists, presumably due to its
metabolic vulnerability, with cimetidine being an exception.
The use of such compounds has now been almost completely
superseded by the prescription of alternative proton pump
inhibitors such as esomeprazole.
Imidazole containing drugs can be subdivided into two classes:
monocyclic imidazoles and benzimidazoles. The former is
represented by three drugs targeting hypertension losartan (157,
Cozaar), olmesartan (158, Benicar), eprosartan (159, Eprozar)
as well as nausea (ondansetron (119, Zofran)) (Figure 5). All of
these drugs aptly highlight a different synthetic approach to the
imidazole core. Early antagonists of the angiotensin II receptor
were of a peptidic nature, suffered from poor bioavailability and
also showed some agonistic activities. The first non-peptide
antagonists were developed in the early 80’s. Although these
compounds were selective for the AT2 receptor, they bound
only weakly to their target protein. On examining the
angiotensin II amino acid sequence, researchers took notice of
an acidic residue on the NH2 terminus. Consequently, a
carboxylic acid moiety was added to the designed ligand
improving affinity for the AT2 receptor. However, the polar
nature of the carboxylic acid group caused this compound to
suffer from poor absorption and low bioavailability. At this
stage a classical bioisostere exchange, i.e., replacing a
carboxylic acid group with a tetrazole ring, was performed
which resulted in increased lipophilicity [48] and the develop-
ment of the orally active losartan.
In the absence of a crystal structure, mutation studies have
shown that the AT2 antagonists such as losartan bind to an
active site located within the membrane-bound part of the
receptor, which is different to that of the peptide agonist.
Further studies led to the discovery of valsartan, where the
imidazole ring of losartan is replaced by an N-acylated amide
which is suggested to mimic the C-terminus of angiotensin II
[49].
The imidazole ring of losartan, an antihypertensive and
angiotensin II blocker is formed in a condensation reaction
between valeroamidine 160 and dihydroxyacetone [50]. It was
found that direct chlorination of the imidazole 162 also forms
the dichlorination product 164 (as shown in Scheme 33) with
formaldehyde as a by-product which proved difficult to
suppress and made purification of the reaction mixture problem-
atic. Hence, a sequence involving silyl protection, chlorination
and deprotection was established which gave the desired pro-
duct in 90% overall yield (Scheme 33).
Alternatively, glycine can be reacted with methyl pentan-
imidate 169 to form the corresponding amidine 171 in high
yield. Cyclisation, followed by a Vilsmeier-type reaction then
furnishes the key chloroimidazolyl building block 172 in good
yield (Scheme 34) [51].
More recently, Zhong and co-workers [52] reported a highly
efficient one-pot procedure starting from N-acylated α-aminoni-
triles 173. The desired 2,4,5-trisubstituted imidazole core 178 is
formed in high yield in the presence of carbon tetrachloride and
triphenylphosphine (Scheme 35). Mechanistic studies showed
that the related imidoyl compounds do not themselves undergo
ring closure to form imidazoles and it was therefore proposed
that the reaction between carbon tetrachloride and triphen-
ylphosphine to generate dichlorotriphenylphosphorane and
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Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
(dichloromethylene)triphenylphosphorane was pivotal. The
amidonitrile substrate 173 can then react with both species to
form seven-membered cyclic intermediate 175 which collapses
to form the imidazole compound.
The structurally related imidazole core of olmesartan is formed
in a different fashion (Scheme 36). Condensation between
diaminomaleonitrile and trimethyl orthobutyrate furnishes the
trisubstituted imidazole 181 in high yield [53,54]. Acid-medi-
ated nitrile hydrolysis followed by esterification results in the
corresponding diester unit 182. Treatment of 182 with four
equivalents of methylmagnesium chloride in a mixture of
diethyl ether and dichloromethane selectively provides tertiary
alcohol 183. In subsequent steps this imidazole is alkylated with
the tetrazole containing biphenyl appendage, followed by ester
hydrolysis and alkylation of the resulting carboxylate with
4-(chloromethyl)-5-methyl-2-oxo-1,3-dioxole to yield
olmesartan (Scheme 36).
The imidazole motif present in ondansetron (119), a prototypic
5-HT3 receptor antagonist, is incorporated into the molecule by
substitution of a trimethylammonium functionality of an
advanced intermediate 188 by 2-methylimidazole (187,
Scheme 37) [55]. Alternatively, this substitution can be
performed on a cyclohexenone derivative prior to the Fischer
indole synthesis (Scheme 27) [38]. The required imidazole 187
itself can be prepared via a variety of methods. For example, a
process involving acetaldehyde, glyoxal and ammonium
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Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
carbonate furnishes the desired compound in an excellent 95%
yield (Scheme 37). Also, a condensation reaction between
ethylenediamine and acetic acid catalysed by γ-Al2O3 at high
temperatures gives 2-methylimidazole (187) in approximately
90% yield [56].
Elz and Heil [57] prepared the 1,2,3,9-tetrahydro-4H-carbazol-
4-one (140) by the reaction of phenylhydrazine (138) with
cyclohexan-1,3-dione (Scheme 38). Classical N-methylation
with dimethyl sulfate followed by introduction of an exocyclic
double bond using paraformaldehyde in DMF under acidic
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Scheme 38: Alternative route to ondansetron and its analogues.
conditions furnishes the Michael acceptor 189, which then
undergoes conjugate addition with various amines (Scheme 38).
This route has been used to prepare several ondansetron
analogues based on different amine components.
Benzimidazoles
Nearly all  benzimidazole containing drugs such as
esomeprazole (190, Nexium), omeprazole (191, Prilosec),
lansoprazole (192, Prevacid), pantoprazole (193, Protonix) and
rabeprazole (194, Aciphex) are proton pump inhibitors. The
common feature in their synthesis is the double condensation of
a 1,2-diaminobenzene with potassium ethylxanthate (196) [58].
A typical synthesis of the methoxybenzimidazole system
present in esomeprazole (omeprazole) and lansoprazole is
shown in Scheme 39. For esomeprazole the subsequent steps
involve an S-alkylation as well as an asymmetric oxidation of
the newly formed thioether [59,60].
Additional structural diversity in the aniline component can be
introduced by protection, nitration, deprotection and reduction
of the starting amine compound 201. Scheme 40 for instance
shows this in the synthesis of the benzimidazole core of panto-
prazole [61].
The benzimidazole ring in rabeprazole (194, Figure 6) is only
substituted at position 2 and can be easily prepared by the same
procedure.
Figure 6: Structure of rabeprazole 194.
In a similar strategy, the benzimidazole structure 210 in the
angiotensin II antagonist candesartan (204, Atacand) is formed
from an advanced diaminobenzene derivative, which in turn is
prepared by a tin-mediated nitro reduction to form a highly
substituted diaminobenzene (Scheme 41). This general strategy
involving initial alkylation of 207 is often employed to control
the regioselectivity of the imidazole formation. The benzimida-
zole ring is then assembled by treating this diamine with
tetraethyl orthocarbonate under Lewis acid conditions. The syn-
thesis is concluded by installation of the tetrazole ring and
acetal side chain, the latter is cleaved under physiological
conditions, making candesartan a pro-drug in the same way as
olmesartan [62]. This synthesis of the benzimidazole precursor
makes use of a 1,2,3-trisubstituted nitrophthalic acid 205, which
had to be selectively monoesterified and subjected to a Curtius
rearrangement, which is cumbersome when the reaction is
scaled up. Alternative routes to such trisubstituted benzenes
include directed ortho-lithiation of 1,3-disubstituted benzenes
followed by trapping of the anion with a nitrogen electrophile
[63]. As a result a new route to access the key building block
has been proposed which makes use of a less widely utilised
acid catalysed rearrangement of methyl N-nitroanthranilate
(212) which is obtained by N-nitration of methyl anthranilate
(211, Scheme 42). Alkylation of the intermediate with the
biphenylmethyl bromide 208 under mildly basic conditions
yields adduct 213. Upon treatment of this compound with 80%
aqueous sulfuric acid a rearrangement to furnish a mixture of
the 3- and 5-nitro derivatives occurs, which unfortunately at this
stage, could not be separated by crystallisation. However, when
this mixture was subjected to catalytic hydrogenation with
Raney nickel a separable mixture of the corresponding
diaminobenzoates was obtained (Scheme 42) [64].
Telmisartan (217, Micardis) is a well known angiotensin II
receptor antagonist used in the treatment of hypertension and,
heart and bladder diseases. Its pharmacophore consists of two
linked benzimidazoles and a biphenyl unit (Scheme 43). As
shown previously, such benzimidazoles can be formed through
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Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
the condensation reaction of a 1,2-diaminobenzene and a suit-
able functionalised carbonyl compound. However, in the case of
telmisartan other inherent functionalities such as an ester are
present which leads to the formation of several by-products and
consequently significantly lower yields. Another obvious draw-
back of the initially described route [65] when considering scale
up, is the number of sequential steps in the synthesis (8 steps,
21% overall yield) (Scheme 43).
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Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Hence an improved synthesis was sought [66]. This revised
route utilised a palladium-mediated reduction of the highly
substituted nitrobenzene derivative 219 to afford aniline 224
which under basic conditions ring closes to the corresponding
benzimidazole 225. Under the same reaction conditions, the
hydrolysis of the methyl ester also occurs which allows the
introduction of the second imidazole group in the subsequent
condensation step. Sterically directed alkylation of the free
imidazole nitrogen with the required biphenyl derivative 223 in
basic media yields the methyl ester 226 which is isolated, after
work-up and solvent removal, as the hydrochloride salt in 85%
yield. HPLC analysis showed a purity of >99.5% which is by
far superior to the previously reported synthesis [65]. Finally,
hydrolysis of the methyl ester provides telmisartan in an overall
yield of about 50% compared to 21% as previously obtained
(Scheme 44).
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Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
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Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Imidazopyridine
Zolpidem (227) is a non-benzodiazepine hypnotic, and is part of
the imidazopyridine class of pharmaceuticals. It is an agonist
for the target receptor of γ-aminobutyric acid (GABA), an
inhibitory neurotransmitter. Zolpidem binds to GABA receptors
at the same site as typical benzodiazepines. This drug is
preferred to benzodiazepines for long term use since benzo-
diazepines lead to a higher tolerance as well as physical depend-
ence. The standard route to this scaffold is the cyclocondensa-
tion of a functional 2-aminopyridine with an α-bromo-carbonyl
compound [67,68]. In the case of zolpidem, the amide moiety in
the 3-position of the ring system is introduced via a
Friedel–Crafts/Mannich-type alkylation starting either from
formaldehyde and dimethylamine or 2,2-dimethoxy-N,N-
dimethylacetamide (Scheme 45).
Scheme 45: Synthesis of zolpidem.
In a recent study a more straightforward and general copper-
catalysed three component coupling leading to imidazo-
pyridines has been reported [69]. For this reaction 2-amino-5-
methylpyridine (228) was condensed with an aldehyde to form Figure 7: Structure of celecoxib.
an intermediate imine to which is added a terminal alkyne in the
presence of copper(I) chloride. A copper(II) triflate catalyst is
then used to promote a Lewis acid promoted 5-exo-dig
heteroannulation to furnish, after chromatography, the bicyclic
structure in good overall isolated yield (Scheme 46).
Despite this synthesis being much shorter and convergent it has
some limitations since the entire procedure needs to be
performed in a glove box and has consequently only been
reported on small scale.
Pyrazole
Selective inhibitors of cyclooxygenase-2 (COX-2) are widely
used for their anti-inflammatory effects and have shown less
gastrointestinal side effects when compared to other anti-
inflammatory agents, notably non-steroidal anti-inflammatory
drugs (NSAIDs) such as aspirin and ibuprofen, which inhibit
both COX-1 and COX-2. The central ring is usually a five-
membered aromatic system, which is diaryl-substituted with a
(Z)-stilbene-like linking structure. A polar sulfonamide group or
biologically equivalent unit is usually present at the para-posi-
tion of one of the aryl rings and is believed to promote binding
to a hydrophilic pocket close to the active site of COX-2. Cele-
coxib (235, Celebrex, Figure 7) belongs to the group of
selective COX-2 inhibitors acting on the prostaglandin G/H
synthase 2 as well as 3-phosphoinositide-dependent protein
kinase 1 and is marketed by Pfizer. Interestingly, celecoxib has
also been approved for familial adenomatous polyposis demon-
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Scheme 47: Preparation of celecoxib.
strating its ability to induce apoptosis in certain cancer cell lines
[70]. As this activity is not shared with all COX-2 inhibitors, it
is believed that the structural features such as the polar sulfon-
amide group, the lipophilic tolyl moiety and the trifluoro-
methylated pyrazole core with its negative electrostatic poten-
tial play a key role in apoptosis induction. Consequently, the
anti-inflammatory and apoptosis inducing properties of cele-
coxib are assumed to result via different modes of action.
In a recent study [71], celecoxib has also been shown to be a
rapid, freely reversible, competitive inhibitor of COX-1. This
result was supported by X-ray crystallographic evidence, where
celecoxib was shown to bind to one subunit of the COX-1-
dimer, implying that drugs like aspirin then bind to the other
monomer of the same enzyme consequently slowing down the
irreversible acetylation of a serine residue by aspirin itself. This
finding is relevant as aspirin is clinically used in combination
with celecoxib to attenuate its cardiovascular side effects. Based
on this in vitro study, it is suggested that the cardioprotective
effects of low-dose aspirin on COX-1 might be reduced when
administered with celecoxib. Further studies are currently
underway to elucidate the full sympathetic action of co-admin-
istration.
The common synthetic route to the diarylpyrazole ring of cele-
coxib (235) is a direct condensation of the 1,3-dicarbonyl com-
pound 236 and the substituted hydrazine 237 [72,73]
(Scheme 47).
The immediate downside to this approach is the generation of
regioisomeric mixtures. However, this is often of minor
concern. In the commercial process only 2–5% of the unwanted
regioisomer is produced, with the purified pyrazole being
obtained by crystallisation. It has been claimed that minimising
the diketone’s exposure to water prior to its reaction with the
hydrazine significantly reduces the formation of the unwanted
regioisomer by avoiding the formation of a hydrate at the car-
bonyl bearing the more electronegative CF3-group. Alter-
natively, in order to circumvent the regioselectivity issue, other
pyrazole syntheses have been used. For example, the substi-
tuted aryl hydrazine 237 can be reacted with trifluoromethyl
butynone in a one pot reaction. A Michael addition/cyclisation
sequence renders only the desired regioisomer of the pyrazole
[74]. However, preparation of the alkyne intermediates involves
a number of steps and often requires extensive column chroma-
tography, which makes it an unattractive method for synthesis
on a larger scale (Scheme 48).
Scheme 48: Alternative synthesis of celecoxib.
A novel 1,3-dipolar cycloaddition between a nitrile imide 244
and an appropriately substituted olefin 245 has also been used
to obtain the corresponding trisubstituted pyrazole [75]. The
final synthesis and its dipole precursor are represented in
Scheme 49.
Since this is a LUMO-dipole/HOMO-dipolarophile controlled
reaction, an electron-rich alkene is required. Therefore, when
the morpholine derived enamine 245 was used the desired
1,3,5-substituted pyrazole was formed with 100% regiose-
lectivity (Scheme 49). This high regioselectivity is only
obtained when a 1,1-disubstituted enamine is used, the corres-
ponding 1,2-disubstituted enamine yields mainly the other
regioisomer.
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Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Indazole
Pazopanib (246, Votrient) is a new potent multi-target tyrosine
kinase inhibitor for various human cancer cell lines. Pazopanib
is considered a promising replacement treatment to imatinib and
sunitinib and was approved for renal cell carcinoma by the FDA
in late 2009. The indazole system is built up via diazotisation
and spontaneous cyclisation of 2-ethyl-5-nitroaniline (247)
using tert-butyl nitrite. The resulting indazole structure 249 can
be methylated entirely regioselectively with either Meerwein’s
salt, trimethyl orthoformate or dimethyl sulfate. A tin-mediated
reduction of the nitro group unmasks the aniline which under-
goes nucleophilic aromatic substitution to introduce the
pyrimidine system with the formation of 253. Methylation of
the secondary amine function with methyl iodide prior to a
second SNAr reaction with a sulfonamide-derived aniline
affords pazopanib (Scheme 50) [76,77].
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Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
1,2,4-Triazole
Although many common antifungal drugs contain at least one
1,2,4-triazole ring, barely any of these drugs are represented in
the top 200 drugs based on the value of sales. This observation
obviously reflects more the price differential of the drug class
rather than the utility of the heterocycle. In general, the triazole
containing drugs belong to two groups of therapeutic agents:
selective and non-steroidal aromatase inhibitors which are used
in the treatment of early and advanced breast cancer in post-
menopausal women, e.g., letrozole (256, Femara) and anastro-
zole (257, Arimidex) and 5-HT1 agonist triptan drugs such as
rizatriptan (76, Maxalt) which are prescribed for migraine head-
aches. The large scale syntheses of all these compounds use the
commercially available 1,2,4-triazolyl sodium salt 258 in an
alkylation reaction with the corresponding benzyl bromide
derivative as the key step (Scheme 51) [78].
One major problem with this route towards anastrozole (257)
(Scheme 51) is the formation of the non-desired regioisomer,
which is often produced in between 10–20% and must be
removed by means of crystallisation which results in a major
loss of material [79]. In order to circumvent the formation of the
undesired regioisomer, a strategy that is often used is to react
the corresponding benzyl bromide component first with
4-amino-1,2,4-triazole (266) to form a quaternary ammonium
salt. The latter can be deaminated to give anastrozole with no
isomeric impurities (Scheme 52) [79].
Scheme 52: Regioselective synthesis of anastrozole.
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Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Other synthetic routes to 1,2,4-triazoles have also been
reported. For example, the desired triazole ring of anastrozole
can be obtained by reacting an appropriately substituted
hydrazine hydrochloride salt 269 with triazine (270)
(Scheme 53) [80].
It has been proposed that this novel transformation occurs by a
two step process: Initially, a molecule of triazine undergoes
condensation and ring cleavage with the hydrazine to generate
formamidrazone 271 which then immediately reacts with a
second molecule of triazine to yield the 1,2,4-triazole [81].
Hence, in this case the triazine can be considered as a form-
amide donor.
Rizatriptan (76) has also been prepared by both the above
mentioned procedures, i.e., via the pre-made triazole or by treat-
ment of a hydrazine hydrochloride salt with triazine
(Scheme 54) [82]. Indeed, the latter protocol has been further
expanded to make use of additional formamide surrogates such
as a formamidinium salt 273 or Gold’s reagent (274)
(Scheme 54).
Sitagliptin (275, Januvia) is a recently developed oral anti-
diabetic drug which belongs to the dipeptyl peptidase DPP-IV
inhibitor class. The inhibition of DPP-IV leads to increased
incretin levels and the inhibition of glucagon release.
Consequently, insulin secretion increases leading to decreased
blood glucose levels in diabetes type II patients. Structurally,
this novel antihyperglycaemic consists of a fluorinated β-amino
acid which is coupled to a trifluoromethylated triazolo-
piperazine (Scheme 55). In SAR studies this fused heterocycle
was found to be more metabolically stable compared to earlier
leads that contained a simple piperazine ring. Furthermore, the
triazolopiperazine is not only involved in a tight H-bond
network within the active site of DPP-IV, but also in π-stacking
with the aromatic ring of a nearby phenylalanine residue, whilst
the trifluoromethyl group interacts with serine and arginine
residues in a lipophilic pocket (Figure 8) [83].
In the discovery chemistry route [84] the heterocycle core was
prepared from a SNAr reaction between chloropyrazine (276)
and excess hydrazine. Subsequent treatment of the substituted
intermediate with trifluoroacetic anhydride furnished the corres-
ponding bis-hydrazide 278 which underwent cyclisation at elev-
ated temperatures in the presence of polyphosphoric acid.
Finally, the partial hydrogenation of triazolopyrazine derivative
279 with palladium on carbon gave the core triazolopiperazine
280. This was then coupled with carboxylic acid unit 281 under
standard peptide bond forming conditions and subjected to pal-
ladium catalysed debenzylation to liberate the free amine func-
tionality of sitagliptin (275) (Scheme 55).
An inherent problem with this synthesis was the necessity for
excess hydrazine in the first step of the sequence in addition to a
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Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
requirement for an expensive and only moderately efficient pal-
ladium reduction in the penultimate step. Furthermore, the
chloropyrazine starting material also proved to be unstable
under a series of reaction conditions and gave rise to numerous
by-products. An improved route was developed for the com-
pounds large scale manufacture. The refined process route
(Scheme 56) starts with a sequential bis-acylation of hydrazine
with ethyl trifluoroacetate and chloroacetyl chloride [85]. The
resulting hydrazide 283 was then subjected to cyclodehydration
using phosphoryl chloride to give a chloromethyl oxadiazole
derivative 284. In a cleverly staged transformation, this com-
pound was treated with diaminoethane to yield the piperazine
ring 285, which, on heating under reflux in methanol, under-
goes a further condensation with the attached hydrazide to
furnish the desired triazolopiperazine ring 280 directly.
Scheme 56: The process route to sitagliptin key intermediate 280.
A novel and very promising HIV treatment is Pfizer’s mara-
viroc (286, Celsentri). HIV uses a member of the G-protein
coupled receptor family called CCR-5 as an anchor to attach
itself to white blood cells such as T-cells and macrophages fol-
lowed by viral fusion and entry into white blood cells. Mara-
viroc blocks this pathway by acting as an antagonist for the
CCR-5 receptor hence disrupting HIV life cycle. The structural
features of this molecule are a geminal difluorocyclohexyl
carboxamide which is linked to a β-aminoacid, and a tropinone-
type unit bound to a 1,2,4-triazole ring. Relatively simple and
straightforward chemical transformations are used to assemble
the main fragments of maraviroc such as amide bond formation
and reductive amination (Scheme 57) [86]. The triazole ring
incorporation is achieved at an early stage by N-acylation of the
tropinone fragment 287 with 2-methylpropanoyl chloride (288).
The resulting amide 289 is then converted to the corresponding
imidoyl chloride 290 using phosphorous pentachloride in
dichloromethane (which proved to be superior to phosphoryl
chloride) followed by condensation with acetic hydrazide (291).
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Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
It was found that the dryness of the acetic hydrazide was crucial
in order to minimise the hydrolysis of the starting amide 289.
Benzodiazepines are a well known class of compounds with a
wide range of CNS-related activities. Moreover, the attachment
of a third ring has been found to impact greatly on the pharma-
cological profile of these drugs. A representative of this com-
pound class is alprazolam (297, Xanax) which contains a 1,2,4-
triazole fused to the benzodiazepine core. The synthesis of this
molecule [87,88] (Scheme 58) can be accomplished in a short
sequence of steps starting by acylation of 2-amino-5-chloroben-
zophenone (298) with chloroacetyl chloride (281) to give the
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Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
amide derivative 299. The latter undergoes an interesting ring
closure reaction in the presence of hexamine and ammonium
chloride and the resulting seven membered lactam 300 can then
be converted into its thioamide analogue 301 with P2S5 in
pyridine. Finally, the reaction of 301 with acetyl hydrazide
(291) catalysed by acetic acid furnishes the triazole ring fused
to the benzodiazepine core.
Another approach [89] makes use of 1,4-benzodiazepine-N-
nitrosamidine 302 as the starting material which when treated
with acetyl hydrazide (291) undergoes the final ring closure.
This procedure can also be employed to prepare the related
series of imidazobenzodiazepines if TosMIC (303) or the
aminopropanol 304 are used as nucleophiles (Scheme 59).
Triazole containing antifungal compounds (Figure 9) are a well
known group of pharmaceuticals but only a few members are
represented in the list of best selling drugs, e.g., itraconazole
(307, Sporanox), ravuconazole (308, BMS-207147) and
voriconazole (309, Vfend).
All members of this class share a common biological activity
being inhibitors of fungal cytochrome P-450 oxidase-mediated
synthesis of ergosterol. Itraconazole, marketed by Janssen
Pharmaceuticals, consists of two triazole subunits as well as a
central diarylpiperazine unit (Figure 9). In one synthesis of
itraconazole [90] 1,2,4-triazole was introduced via direct
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
nucleophilic substitution. However, due to the previously
discussed regioselectivity issues, extensive chromatographic
purification was required following this step. In the latter stages
of the synthesis, the elaborated aniline derivative 310 was
trapped with phenyl chloroformate to form the corresponding
carbamate which was then converted into triazolone 314 by a
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Scheme 60: Synthesis of itraconazole.
double condensation reaction with hydrazine and formamidine.
Finally, simple attachment of an isobutyl group completes the
synthesis (Scheme 60).
1,2,3-Triazole
Rufinamide (315, Inovelon) is Novartis’ new CNS-active com-
pound used in the treatment of epilepsy. The common route
[91,92] to the triazole ring present in this compound involves
the reaction of 2,6-difluorobenzyl azide (316) with 2-chloro
acrylonitrile 317 at temperatures around 80 °C in aqueous
medium (Scheme 61). This transformation, which can be
described either as a conjugate addition–elimination sequence
or as a [3 + 2] cycloaddition followed by elimination was found
to work best in a biphasic system, where the resulting HCl was
retained in the aqueous phase thereby reducing overall amounts
of polymerisation of the 2-chloroacrylonitrile starting material.
In the final step the nitrile group is quantitatively hydrolysed
under basic conditions to the primary amide.
Apart from this patented route, an improved approach has
recently been described [93]. In this work it was shown that the
highly toxic and flammable 2-chloroacrylonitrile can be readily
Scheme 61: Synthesis of rufinamide.
substituted with the less toxic and less expensive methyl
3-methoxyacrylate. After thermal cycloaddition, the methyl
ester is converted to the corresponding amide by the addition of
methanolic ammonia. Overall, this process can be performed as
a single pot procedure on a multi-gram scale to afford rufin-
amide in a similarly high yield and generating less waste.
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Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Tetrazole
The tetrazole motif as a bioisostere for a carboxyl group is a
well documented structural replacement represented by five
angiotensin II antagonists in the top selling 200 drugs. In order
to generate the tetrazole ring, a nitrile is reacted with an azide,
most commonly tributyltin azide. This is illustrated by the
Novartis/Ciba-Geigy synthesis of valsartan (319, Diovan),
where the tetrazole ring is constructed in the last step of the
sequence (Scheme 62) [49].
Scheme 62: Representative tetrazole formation in valsartan.
The same approach is repeated in other angiotensin AT2 antag-
onists, such as olmesartan (158), candesartan (204) or irbesartan
(321) (Figure 10).
The tetrazole ring has also been introduced at the beginning of
the synthesis, however, the heterocyclic ring, which has to be
carried through all subsequent steps, often requires protection.
One common protecting group is the trityl group as used in the
synthesis of losartan (157) (Scheme 63) [51,94].
The tetrazole ring also appears in cilostazol (325, Pletal) which
is a selective PDE3 phosphodiesterase inhibitor used as a
platelet aggregation inhibitor. The tetrazole ring 327 is prepared
via the reaction of an in situ generated imidoyl chloride and
Scheme 63: Early stage introduction of the tetrazole in losartan.
hydrazoic acid delivered as a 10% solution in benzene [95,96].
Subsequent alkylation under Williamson conditions provides
the final compound 325 in good yield (Scheme 64).
Thiazole
The first example of a thiazole in the top 200 drugs listings is
cefdinir (329, Omnicef, Figure 11), a semi-synthetic third
generation cephalosporin which is administered orally and has
an extended antibacterial activity against both gram-positive
and gram-negative bacteria. The main feature of cefdinir is that
it shows excellent activity against Staphylococcus species [97].
The thiazole ring in cefdinir shows that the heterocyclic struc-
ture in a drug not only affects its pharmacodynamic properties
but can also influence its kinetics. It is believed that in the
digestive tract iron(II) ions form chelate complexes with the
thiazole ring and the oxime nitrogen atom and hence reduce the
bioavailability of cefdinir [98].
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Scheme 64: Synthesis of cilostazol.
Scheme 65: Semi-synthesis of cefdinir.
Figure 11: Structure of cefdinir.
The convergent semi-synthesis of cefdinir can be achieved by
coupling 7-amino-3-vinyl-3-cephem-4-carboxylic acid ester 335
with an advanced carboxylic acid derivative 334 which contains
the elaborated thiazole motif (Scheme 65). This heterocyclic
acid can itself be obtained from ethyl acetoacetate which is
converted to an oxime 330 and α-chlorinated prior to a
Hantzsch-type thiazole synthesis with thiourea in ethanol and
N,N-dimethylaniline as the base [99]. Simultaneous trityl
protection of the oxime and primary amine furnishes the desired
coupling partner 334 in good overall yield. Hydroxide promoted
ester hydrolysis was followed by treatment with phosphoryl
chloride and the resulting acyl chloride coupled with the bio-
logically derived lactam 335. All three trityl protecting groups
are simultaneously cleaved with TFA to furnish cefdinir 329.
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Scheme 66: Thiazole syntheses towards ritonavir.
The HIV-1 protease inhibitor ritonavir (337 ,  Norvir,
Scheme 66) consists of two differently substituted thiazole
rings, which are introduced at the later stages in the synthesis of
this peptidomimetic antiviral compound. Interestingly, ritonavir
itself is a result of further improvements on earlier candidates
for the treatment of AIDS. A lead compound (344, A-80987)
was also described by Abbott bearing pyridine rings on both
ends of the peptidomimetic structure, which resulted in good
bioavailability as required for orally administered drugs, but
this compound had an insufficient plasma half-life. This was
ascribed to the more electron-rich nature of the pyridine rings
when compared to many other nitrogen containing heterocycles
leading to a higher metabolic susceptibility. Consequently, the
pyridine rings were replaced with less electron-rich thiazoles
which resulted in both good bioavailability and a long plasma
half-life. In addition, H-bonding of the 5-substituted thiazole to
the backbone of Asp-30 of the HIV-1 protease is reported to be
crucial with other substitution patterns showing reduced
potency. The thiazole on the left-hand side is derived from the
condensation between 2-methylpropane thioamide 338 and
dichloroacetone 339 [100], whilst the other thiazole is obtained
from the inexpensive 2,4-thiazolidinedione (341, Scheme 66)
[101].
The dopamine D2-agonist pramipexole (345, Mirapex) consists
of a fused bicyclic tetrahydrobenzothiazole motif, which is also
prepared by a Hantzsch-type condensation between an α-brom-
inated protected form of 4-aminocyclohexanone 346 and
thiourea. Following deprotection, resolution with L-(+)-tartaric
acid gives access to the S-enantiomer which undergoes
reductive amination and can be isolated as the dihydrochloride
salt (Scheme 67) [102].
Alternatively, the thiazole ring can be made in a one pot reac-
tion from the corresponding enamine 350, which is reacted with
Scheme 67: Synthesis towards pramipexole.
elemental sulfur to give the α-thioketone 351 (Scheme 68). This
in turn can be treated with cyanamide to furnish the racemic
thiazole 345 [103]. Resolution with (+)-ditoloyl-D-tartrate
allows isolation of the desired S-enantiomer after treatment of
the diastereomeric salt with sodium carbonate.
Famotidine (352, Pepcidine) is an H2-receptor antagonist
similar to cimetidine which inhibits many isoenzymes of the
hepatic CYP450 system and has the additional side effect of
increasing the amount of gastric bacteria such as nitrate reduc-
ing bacteria. The structure of this ulcer therapeutic is very
interesting and consists of a thiazole substituted guanidine and a
sulfamoyl amidine. Although famotidine is orally administered,
its solubility and hence bioavailability under acidic conditions,
as found in the stomach, is relatively low. Recent reports have
appeared that describe famotidine as a good ligand for various
transition metals including copper and cobalt forming
tetradentate {N,N,S,N}-coordination spheres as shown by single
X-ray analysis [104]. It therefore seems feasible that certain
common bioavailable cations might be involved in the absorp-
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Scheme 69: Synthesis of famotidine.
Scheme 68: Alternative route to pramipexole.
tion and activation of this thiazole containing compound. The
synthesis of the thiazole ring [105,106] can be accomplished
again by condensation of thiourea with dichloroacetone 340.
Alkylation of the isothiourea sulfur with 3-chloropropionitrile
(354) and hydrolysis results in the formation of the substitution
product 355. Functionalisation of the resulting 2-amino group
on the thiazole ring using benzoyl isothiocyanate generates the
guanidine precursor 357. A standard sequence of methylation
and exchange with ammonia simultaneously cleaves the
benzoyl group and unmasks the guanidine unit 358. At the other
peripheral of the molecule the nitrile functionality is converted
to the imidate and subsequently coupled with sulfamide to yield
famotidine (Scheme 69).
A final example of a thiazole containing drug is given in the
novel xanthine oxidase inhibitor febuxostat (359, Uloric) which
was approved by the FDA in 2009. This inhibitor works by
blocking xanthine oxidase in a non-competitive fashion.
Consequently, the amount of the oxidation product uric acid is
reduced. Thus it is an efficient treatment for hyperuricemia in
gout. In order to prepare febuxostat first a synthesis of the non-
commercial 4-isobutoxy-1,3-dicyanobenzene building block
(363), has to be conducted. An elegant way of achieving this
was shown through the reaction of 4-nitrocyanobenzene (360)
with potassium cyanide in dry DMSO followed by quenching
with isobutyl bromide under basic conditions (Scheme 70). It is
suggested that a Meisenheimer-complex intermediate 361 is
initially formed, which after rearomatisation, undergoes nucleo-
philic aromatic substitution of the nitro group by the DMSO
solvent [107]. Upon hydrolysis and O-alkylation the desired
4-isobutoxy-1,3-dicyanobenzene (363) is obtained in good
overall yield. Subsequently, the less hindered nitrile is
converted to the corresponding thioamide 365 in an intriguing
reaction using thioacetamide (364). The thiazole ring is then
formed by condensation with chloroacetoacetate 366 followed
by ester hydrolysis (Scheme 70).
Ziprasidone (367, Geodon), is an atypical antipsychotic used to
treat schizophrenia as well as mania and related bipolar disorder
(Scheme 71). The exact pharmacological effect of ziprasidone
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Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
is not simple to understand as it affects many subtypes of
dopamine, adrenergic and serotonin receptors. However, like
many antipsychotic drugs its main therapeutic activity is prob-
ably due to its antagonistic action on dopamine receptors. The
molecule comprises of a 1,2-benzisothiazole core, which is
r e a d i l y  p r e p a r e d  f r o m  c o m m e r c i a l l y  a v a i l a b l e
benzo[d]isothiazol-3(2H)-one (369), a saccharin derivative
[108]. The corresponding chloroimidate 370 formed by treat-
ment of compound 369 with phosphoryl chloride is reacted with
excess piperazine to afford intermediate 371 (Route A) [109].
Although this route enabled the synthesis of ziprasidone as its
hydrochloride-salt, the nucleophilic aromatic substitution step
(370→371) was poor and gave only 38% of the desired product
[110]. Therefore an improved process was developed involving
the oxidative coupling of piperazine with bis(2-cyano-
phenyl)disulfide (368) at elevated temperatures [109]. Due to
the use of DMSO as a co-solvent and oxidant, each equivalent
of the disulfide component was then converted into two equiva-
lents of the product making the process more economically effi-
cient. The final union was accomplished using standard Finkel-
stein alkylation conditions furnishing ziprasidone in 90% yield
(Scheme 71) [111].
Beilstein J. Org. Chem. 2011, 7, 442–495.
484
Furan
Mometasone (373, Nasonex) is one of the few examples
amongst the top selling pharmaceutical drugs that contains a
furan ring. Simple furan structures are not normally viable
because of their propensity for rapid metabolism by various oxi-
dation mechanisms. Mometasone is a moderately potent gluco-
corticoid used for the treatment of inflammatory skin disorders,
asthma and allergic rhinitis. Because it is delivered topically or
is inhaled, it is not subject to rapid metabolism. Structurally, it
consists of a chlorinated dexamethasone core which is esteri-
fied with 2-furoic acid at the 17-position (373, Figure 12).
Figure 12: Structure of mometasone.
2-Furoic acid (375) can be obtained via a Cannizzaro-type
disproportionation of furfural (374) which is industrially
produced from corncobs: Annual production ca. 450,000 tons.
Corncobs contain hemicelluloses which degrade to xylose under
acidic conditions. Upon strong heating, xylose is converted to
furfural, which can be distilled from the biomass (Scheme 72).
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
The furfuryl alcohol (376) obtained in the abovementioned
disproportionation (Scheme 72) is also a key starting material
for the peptic ulcer therapeutic ranitidine (377, Zantac). In the
synthesis of this H2-receptor antagonist, furfuryl alcohol is
subjected to a Mannich reaction with paraformaldehyde and
dimethylamine hydrochloride. The resultant (5-((dimethyl-
amino)methyl)furan-2-yl)methanol (378) is then treated with
cysteamine hydrochloride (380) which leads to replacement of
the hydroxyl functionality. Finally, coupling of amine 379 with
N-methyl-1-methylthio-2-nitroethenamine (381) furnishes rani-
tidine (Scheme 73) [112].
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
In addition, the antibiotic nitrofurantoin (382, Macrobid) used
in the treatment of urinary infections is based on a nitrofurfural
building block which can be obtained by nitration of furfural
(374) [113]. The isolated derivative, acetal 383, can be
converted to nitrofurantoin via condensation with amino-
hydantoin 384 which itself is obtained from cyclisation of semi-
carbazidoacetic acid under acidic conditions (Scheme 74) [114].
Scheme 74: Synthesis of nitrofurantoin.
Amiodarone (385, Cordarone) is an antiarrhythmic drug
containing a benzofuran ring system. It is one of the most
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Scheme 77: Synthesis of raloxifene.
effective antiarrhytmic drugs. Although it is considered a class
III antiarrhytmic with its mode of action being principally the
blocking of potassium channels, it is anticipated that it is also
capable of targeting additional sodium and calcium channels.
This might explain its general effectiveness, but could also
account for its potentially dangerous side effects. The basic
benzofuran framework is commonly prepared by alkylation of
salicylic aldehyde (386) with chloroacetic acid (387) to give the
dihydrobenzofuran carboxylic acid which after intramolecular
condensation readily decarboxylates (Scheme 75).
Scheme 75: Synthesis of benzofuran.
A more recent synthesis of amiodarone reports the cyclisation
of α-phenoxyhexanal 389 under acidic conditions to yield the
substituted benzofuran 390 (Scheme 76). A Friedel–Crafts acyl-
ation next introduces the aryl ring at the 3-position. Demethyl-
ation, iodination and a final alkylation with a diethylamino-
ethane fragment yields amiodarone [115-117].
Thiophene
Considering the fact that thiophene is a classical bioisostere for
a benzene ring it is not surprising that it is encountered in many
therapeutically active agents. Amongst the drugs containing a
thiophene ring are raloxifene (392, Evista) and olanzapine (399
Scheme 76: Synthesis of amiodarone.
Zyprexa). The former, which is a benzo[b]thiophene, is widely
used as an oral selective estrogen receptor modulator displaying
estrogenic actions on bone (prevention of osteoporosis) and
anti-estrogenic actions on breast and uterus, especially in the
postmenopausal women [118]. The synthesis of the
benzo[b]thiophene core 396 was accomplished by condensing
3-mercaptoanisole (393) with 4-methoxyphenacyl bromide
(394) firstly under basic conditions to affect the SN2 displace-
ment followed by dehydration with polyphosphoric acid at elev-
ated temperatures (Scheme 77) [119]. Further transformations
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Scheme 79: Gewald reaction in the synthesis of olanzapine.
on this scaffold include the introduction of the carbonyl at the
3-position via a Friedel–Crafts acylation and deprotection,
yields raloxifene.
A non-classical approach to this same benzo[b]thiophene core
398 is outlined in Scheme 78 [120]. The vinylic sulfoxide 396
undergoes a formal electrophilic cyclisation under the acidic
conditions followed by aromatisation to furnish the desired
intermediate in high yield.
Scheme 78: Alternative access to the benzo[b]thiophene core of
raloxifene.
Another atypical antipsychotic drug which has been long estab-
lished as a top-selling pharmaceutical is olanzapine (399) which
was first introduced to the market by Eli Lilly in 1996. The
thiophene unit is synthesised by a multi-component reaction
between malononitrile, elemental sulfur and propionaldehyde
(400) in the presence of triethylamine. This Gewald-type
thiophene synthesis is thought to proceed via an initial
Knoevenagel reaction (400→402) followed by the addition of
the sulfur into the nitrile to form thiocyanate 403 which then
ring closes to the aminothiophene product 405. This species is
then employed in a nucleophilic aromatic substitution with
2-fluoronitrobenzene (406) to give the coupled product 407.
Reduction of the nitro functionality produces the corresponding
aniline that readily undergoes ring closure to furnish ultimately
the thienobenzodiazepine 408. Substitution of the pendant
amine group with excess N-methylpiperazine (409) then affords
olanzapine in modest overall yield (Scheme 79) [121].
In a similar process the malononitrile was replaced with the less
toxic methyl cyanoacetate (410) to give the alternative com-
pound 411 (Scheme 80). The previously used nucleophilic
substitution was repeated to furnish the methyl ester analogue
412. Then, in order to avoid the use of the strongly acidic reduc-
tion and cyclisation conditions employed in Scheme 79
(407→408), a milder palladium catalysed hydrogenation was
used. Finally, a one pot intramolecular amide formation fol-
lowed by a TiCl4-mediated reaction to introduce the amidine
function yields olanzapine (Scheme 80) [122].
Three additional thiophene-containing drugs are duloxetine
(414, Cymbalta), tiotropium (415, Spiriva) and Cosopt [dorzol-
amide (416) (Figure 13) and its second active ingredient timolol
(see also Scheme 84)]. However, the syntheses of all three com-
pounds use simple thiophene starting materials, viz. the
carboxylic acid 417, for duloxetine [123], or a Grignard reagent
(418) for tiotropium [124] and thiophene-2-thiol (419) for
dorzolamide [125].
One of the most successful platelet aggregation inhibitors
currently on the market is clopidogrel (420, Plavix) which is a
chiral tetrahydrothieno[3,2-c]pyridine derivative (Scheme 81).
In the favoured synthetic route this tricyclic motif is prepared
by a nucleophilic substitution of α-bromo 2-chlorophenyl aceto-
nitrile (421) with a secondary amine 422. Subsequent hydro-
lysis of the secondary nitrile under phase transfer conditions
delivers the free acid which is converted to the methyl ester
424. In order to obtain the desired S-enantiomer, a classical
resolution with ca. 0.5 equiv of L-camphorsulfonic acid
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Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
(L-CSA) in toluene is used. The desired enantiomer 420 is
collected as a crystalline salt in greater than 98% ee and 88% of
the expected yield (Scheme 81) [126]. The remaining material
can be easily epimerised under mildly basic conditions.
Although the tetrahydrothieno[3,2-c]pyridine structure 422 is
now readily available on a large scale from various commercial
sources, it was originally synthesised in a variety of ways. The
most straightforward route was from thiophene-2-carbaldehyde
(425) which was subjected to a Henry reaction with nitro-
Scheme 81: Synthesis of clopidogrel.
methane. Reduction of the nitro olefin function to the corres-
ponding alkylamine followed by reaction with formaldehyde
gave the corresponding imine 426 [127]. Treatment of the latter
with hydrochloric acid initiates a Pictet–Spengler reaction to
furnish the desired heterocycle in high overall yield
(Scheme 82).
Scheme 82: Pictet–Spengler reaction in the preparation of
tetrahydrothieno[3,2-c]pyridine (422).
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Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
This key compound can also be accessed by assembling the
thiophene ring. In this scenario N-protected 4-piperidone 427 is
subjected to Vilsmeier conditions to produce the reactive
chloroaldehyde species 428 which, upon treatment with ethyl
mercaptoacetate (429), cyclises to the heterocyclic structure
although in only low isolated yield. Simple base hydrolysis of
the ester followed by decarboxylation generates the desired pro-
duct (Scheme 83) [128].
Thiadiazole
Cosopt, an ophthalmic medication, consists of the two active
ingredients dorzolamide (416; Figure 13), a carboanhydrase
inhibitor used as an anti-glaucoma agent, and timolol (432;
Figure 14) a β-adrenergic receptor blocker used to lower intra-
ocular pressure by reduction of aqueous humour production. In
a recent report an X-ray co-crystal structure of timolol within
the β2-adrenergic receptor was disclosed [129]. An overlay of
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Scheme 84: Synthesis of timolol.
this structure with a previous one showing the position of
carazolol (433), an analogue of the previously mentioned
carvedilol (136) β-blocker, shows the binding of these
molecules (Figure 14). Additionally, this data nicely exempli-
fies the stronger binding of timolol, as its morpholine group is
involved in an extra hydrogen-bonding network with nearby
amino acids (Asn, Tyr, Ser) and the thiadiazole motif itself
protrudes deeper into the actual binding pocket when compared
with the carbazole system of carazolol which results in stronger
interactions.
Whilst the synthesis of the thiophene-containing component
(dorzolamide) of Cosopt starts from 2-mercaptothiophene and
elaborates the thienothiopyran motif in a linear multi-step
fashion, the thiadiazole ring of timolol is prepared from an
acyclic precursor (Scheme 84). The active pharmaceutical
ingredient (API) timolol is prepared via a biocatalytic asym-
metric reaction which permits selective access to both enan-
tiomers [130]. Starting from 3,4-dichloro-1,2,5-thiadiazole
(435), which can be prepared from cyanogen (434) and sulfur
dichloride [131], the two chlorides are differentiated by sequen-
tial substitution reactions using morpholine and sodium
hydroxide. The resulting hydroxyl in compound 436 is
alkylated with dichloroacetone to yield a carbonyl compound
437 susceptible to enzymatic reduction with baker’s yeast. The
levorotatory enantiomer thus obtained can be subjected to
Mitsunobu conditions with benzoic acid as the nucleophile and
leads to clean inversion of the stereocentre which thus gives
access to the other enantiomer of timolol. Under basic condi-
tions the chlorohydrin 438 can be converted to the corres-
ponding epoxide which can be ring opened by tert-butyl amine
to furnish timolol (Scheme 84).
A related heterocyclic structure can be found in the skeletal
muscle relaxant tizanidine (440, Zanaflex). This substituted
2,1,3-benzothiadiazole 442 can be prepared by the reaction of
an aromatic diamine 441 on heating with thionyl chloride in the
presence of DMF. Selective nitration followed by an iron-medi-
ated reduction affords the corresponding aniline 443 which
partakes in a nucleophilic substitution of 2-chloro-3,4-
dihydroimidazole (generated in situ from the reaction of the
urea 444 and phosphoryl chloride). Removal of the acetate
group under basic conditions furnishes tizanidine (Scheme 85)
[132].
Isoxazoles and benzisoxazole
The isoxazole ring is a common heterocyclic motif represented
by several of the top-selling small molecule pharmaceuticals.
This ring structure is often encountered as a surrogate of other
nitrogen containing heterocycles such as pyrazoles, pyridines or
pyrimidines [133]. Two specific drugs containing this structure
are leflunomide (446, Arava) and sulfamethoxazole (447,
Bactrim).
Leflunomide is a pyrimidine synthase inhibitor of the DMARD-
type (disease-modifying anti-rheumatic drug) marketed by
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Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 85: Synthesis of tizanidine 440.
Sanofi-Aventis. Unlike NSAIDs, which only deal with symp-
toms of rheumatoid arthritis, DMARDs target the cause of it.
DMARDs are not necessarily structurally or mechanistically
related. The effect of leflunomide is possibly due to its regula-
tion of the immune system via affecting lymphocytes. Its syn-
thesis [134] is relatively straightforward starting with a
Knoevenagel condensation of ethyl acetoacetate (39) and
triethyl orthoformate in the presence of acetic anhydride. The
resulting ethyl ethoxymethylene acetoacetate (448) is next
condensed with hydroxylamine hydrate in methanol to yield
ethyl 5-methylisoxazole-4-carboxylate (449). The ethyl ester is
hydrolysed under acidic conditions and the carboxylic acid
activated with thionyl chloride in DMF for amide formation
with 4-trifluoromethylaniline (450) (Scheme 86).
A related condensation between (E)-4-(dimethylamino)but-3-
en-2-one (451) and hydroxylamine is used in the synthesis of
bactriostatic antibiotic sulfamethoxazole (447) to yield the
equivalent 5-methylisoxazole (452) (Scheme 87). This basic
unit is then nitrated with a mixture of ammonium nitrate in
trifluoroacetic anhydride 240, which is presumed to form the
active trifluoroacetyl nitrate, and converted to the 3-amino-5-
methylisoxazole (453) in a aluminium-amalgam mediated
reduction [135,136]. Sulfonamide formation with the sulfonyl
chloride 454 yields the antibiotic agent 447 (Scheme 87).
The most prescribed therapeutic for schizophrenia is the
benzisoxazole containing antipsychotic risperidone (455,
Risperdal). For this molecule the benzisoxazole ring is formed
via an intramolecular nucleophilic aromatic substitution
between an in situ generated oxime 459 and the adjacent
aromatic ring [137]. The precursor carbonyl derivative 458
arises from a Friedel–Crafts acylation of the difluoroaromatic
457 (the acetate N-protecting group is presumably lost in the
work up). Finally, alkylation of the piperidine ring under
Finkelstein conditions is used to complete the synthesis of
risperidone (Scheme 88).
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Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Conclusion
Having collected data with respect to many different reported
syntheses of drugs containing heteroaromatic five-membered
rings, a number of observations can be drawn. For instance, it
was established that the most common transformations used are
indeed condensations and nucleophilic substitution reactions
(Figure 15) [138,139]. This can be rationalised by considering
that only small molecular weight by-products such as water or
hydrogen chloride/bromide are generated, which are benign and
can be easily removed. Other well represented transformations
include reductions, amide and ester formations, rearrangements
and saponifications, which can be performed in an atom-
economic manner based on numerous well established proto-
cols. On the other hand, other robust transformations such as
oxidations, nucleophilic aromatic substitutions, olefinations,
cycloadditions and metal-mediated transformations appear to be
rarely used. The reasons for this might be the need for stoi-
chiometric reagents leading to large amounts of waste as well as
potential heavy metal contamination. In addition, these reac-
tions are usually accompanied by the release of heat due to
exothermic reaction profiles which might result in difficult to
control and therefore undesired chemical processes.
An additional comment should be made about the time frame of
new reaction uptake within the process environment. For certain
reaction types such as metathesis and C–H activation, which
obviously offer significant synthetic potential, it could be
argued that the length of time required for these reactions to
evolve from research tools to production processes are outwith
the pipeline development times of the drugs under discussion. A
significant body of the literature representing the synthesis of
these drugs date back many years to origins in the late seven-
ties and early eighties. Consequently, it is probably not unex-
pected to see the absence of many of the ‘newer’ chemical
methodologies.
Interestingly, the above-mentioned classes of chemical reac-
tions are most widely applied to a limited number of hetero-
cyclic cores with indoles, triazoles and benzimidazoles being
the most prominent examples to date (Figure 16). It can be
postulated that this is likely due to two possible factors; 1) the
utilisation of so-called ‘me-too drug’ approaches by pharma-
ceutical companies or 2) the fact that these are privileged struc-
tures which avoid the limitations of many other aromatic
heterocycles in biological systems such as toxicity. However,
the more recent trend seems to indicate a move towards more
diverse scaffolds. This might be ascribed to the massive efforts
of the pharmaceutical industry to find new drug classes, but
could also be an indication of the patenting approaches used to
protect more comprehensively these new developments.
Furthermore, this move towards novel heterocyclic structures
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also allows for more flexible substitution patterns permitting
extensive SAR studies through efficient high throughput screen-
ings commonly used today.
Figure 16: The abundance of heterocycles within top 200 drugs
(5-membered rings).
One constant in all the drug syntheses is the shortness of the
reported routes, which typically do not exceed 6–8 steps.
Furthermore, chiral centres are still less well represented in
drugs unless they can be sourced cheaply from the chiral pool
or accessed from commercial suppliers specialised in asym-
metric synthesis, for instance, hydrogenations or enzymatic
transformations/resolutions. It is predicted [140] that the
number of future drugs bearing chirality will increase due to
more reliable and affordable catalytic asymmetric transforma-
tions [141].
Based on the material presented in this review it can be
concluded that most of the reported routes towards well estab-
lished drugs are based on conventional transformations to
furnish the desired compound quickly. However, with
increasing competition between the pharmaceutical companies
and additional pressures from regulatory/government author-
ities, chemical producers will need to adopt improved
processing techniques that encompass a reduced environmental
footprint and deliver the APIs at significantly reduced cost. In
order to achieve the necessary productivity gains future chem-
istry programmes will have to employ a wider range of syn-
thetic transformations targeted at delivering molecules covering
an expanded area of chemical space. This will not be solely
achieved by minor improvements in the efficiency of indi-
vidual chemical reactions but will need the industry to integrate
actively all the new tools and enabling technologies within their
research and manufacturing efforts [142].
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